not only should these' patients be diagnosed and managed by an interdisciplinary group, but every effort should be made to treat all cases within the general orbit of this important national trial. Yours sincerely LIPMANN KESSEL (July, p 467) raises certain interesting points. While it remains unproven from this paper that patients with circulating malignant cells have a better prognosis than those patients in whom they are not demonstrated (the groups are unmatched, with significantly more A and B cases in the groups with circulating malignant cells) the thesis is attractive. If the number of circulating malignant cells is raised by giving fibrinolytic agents such as urokinase, would not the use of other methods to prevent thrombosis and platelet adhesion give similar results? With the great interest over the last few years in the prophylactic treatment to prevent deep vein thrombosis after many surgical procedures by the use of low-dose heparin or dextran infusion it would be pertinent to ask whether any of your readers have found a similar beneficial effect from these drugs, on the prognosis of both colorectal and other carcinomas.
It has also been suggested that protease and collagenase inhibitors such as aprotinin have a similar beneficial effect on reducing metastases in experimental animals. Yours faithfully P R HAWLEY 9 August 1976 A copy of Mr Hawley's letter was sent to Mr White and his co-authors and their reply appears below:
Dear Sir, We fully accept the statistical limitations in analysing our data and deliberately avoided suggesting a high degree of significance in such a small group with differing numbers of unmatched Dukes A, B and C cases -merely stating P values for the two main groups.
However, among the C cases (the most numerous group) it is worth noting that there was a 40 % survival when circulating malignant cells were present but only an 11% survival when malignant cells were not found. Our data were actually analysed as regards the overall survival at ten years in relation to the various states and as regards A, B and C classification within each group. The numbers involved are on the small side but when assessing the distribution of survival between categories A, B and C at ten years, there is a significant difference between dead and alive patients (P=0.5 %), with 'dead' showing excess C and shortfall in A and 'alive' the reverse.
There has been a great deal of experimental work with animal tumours suggesting that in certain systems anticoagulants and other agents such as ancrod (purified Malayan pit viper venom) can reduce metastases. The first clinical survey of patients on long-term anticoagulants which suggested a benefit was that by Michaels (1964, Lancet ii, 832) . Studies by Thornes (1972, Journal of the Irish Colleges of Physicians and Surgeons 2, 41) also suggested increased survival in cancer patients receiving anticoagulants. More recently Hoover & Ketcham (1976, personal communication) find an increased survival in anticoagulated patients undergoing operations for osteosarcoma.
All these trials are small and inconclusive. We agree that a retrospective analysis of survival in patients with malignant disease who have had low-dose heparin at the time of operative treatment would be interesting. We are starting a prospective trial of low-dose heparin and anticoagulants in patients with malignant disease. Yours Stage II carcinoma of the cervix gave rise to some hope that we might receive guidance on the management of this problem. In so far as treatment is concerned the papers as reported in the Proceedings (September, pp 673-686) are somewhat disappointing. Dr Cole advocates radium therapy alone for 'early' cases, Mr Feroze radiotherapy followed by surgery and Dr Baker varies her treatment with the histology and with the
